DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Bethesda North Marriott Hotel and Conference Center

2019 年 04 月 23 日 7:00 上午 - 2019 年 04 月 25 日 5:00 下午

5701 Marinelli Road, , North Bethesda, MD 20852 , USA

CMC Workshop

Explore how to utilize effective CMC strategies and execution and how it can help to reduce regulatory burden, enable shorter review timelines, and support post-approval maintenance.

Session 4 Track A: Patient-Centric Quality Standards

Session Chair(s)

Christine  Moore, PhD

Christine Moore, PhD

Executive Director, Global External Advocacy and Standards

Organon & Co., United States

Patient Centric Quality Standards is an evolving approach for setting pharmaceutical quality requirements based upon a wide array of scientific data. The traditional approach of setting drug specifications from limited manufacturing experience can lead to unnecessarily narrow specifications that can jeopardize future ability to successfully manufacture the product. Use of prior knowledge and product specific knowledge can provide justification for wider, yet appropriate drug specifications and support continued supply of quality product to patients.

Learning Objective : At the conclusion of this session, participants should be able to:
  • Understand the potential issues related to specification setting based upon limited manufacturing data
  • Understand the role of prior knowledge and product specific knowledge in specification setting
  • Provide examples of how scientific data can be applied toward specification setting

Speaker(s)

Shrinivas K Murti, PhD, MBA

Speaker

Shrinivas K Murti, PhD, MBA

Merck, United States

Director, Regulatory Affairs CMC

Roger  Quan

Patient-Centric Quality Standards: Impurity Specifications

Roger Quan

Abbvie, United States

Senior Director, Regulatory Affairs CMC

Anthony  Mire-Sluis, PhD

Prior Knowledge in Setting Patient Centric Specifications

Anthony Mire-Sluis, PhD

Astrazeneca, United States

Head of Global Quality

Lawrence  Yu, PhD

Patient Centric Quality Standards

Lawrence Yu, PhD

FDA, United States

Director, Office of New Drug Products, OPQ, CDER

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。